Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Systemic lupus erythematosus (SLE) rarely complicated by Libman-Sacks endocarditis (LSE), and even more exceptionally by therapy- or immune-inflammatory-driven chronic myeloid leukemia (CML).
We report a 19-year-old woman admitted with malar rash, intermittent fever, bilateral leg edema, alopecia and arthralgia. Laboratory tests showed nephrotic-range proteinuria, hypoalbuminaemia, autoimmune haemolytic anaemia, thrombocytopenia, high-titre ANA and anti-dsDNA, hypocomplementaemia, and positive lupus anticoagulant. Transthoracic and transoesophageal echocardiography revealed a 10.5 × 4.2 mm sterile vegetation on the left ventricular aspect of the aortic valve with mild regurgitation, consistent with LSE. Renal biopsy was withheld because of high bleeding risk. Intravenous methylprednisolone pulse (500 mg × 3 days) followed by oral prednisone 40 mg/day, combined with mycophenolate mofetil, hydroxychloroquine, IVIG and warfarin, was initiated (SLEDAI 20).
The valvular vegetation resolved completely within 20 weeks, and proteinuria entered complete remission by month 9. After 21 months of treatment the patient developed asymptomatic leukocytosis (peak 109 × 10⁹/L). Bone-marrow morphology and BCR::ABL1 RT-PCR confirmed chronic-phase CML (p210 transcript, low-risk Sokal/ELTS). Imatinib was started; a deep molecular response (BCR::ABL1 IS 0.003%) was achieved and sustained. The drug was discontinued after 32 months, and treatment-free remission persists to date. SLE has remained inactive on low-dose mycophenolate mofetil and hydroxychloroquine.
This case illustrates that aggressive immunosuppression can induce complete resolution of LSE and underscores the need for lifelong hematologic surveillance in SLE patients, even during remission, to detect rare secondary neoplasms such as CML.
